article_id,journal_title,article_title,author,publication_date,keywords,cleaned_body_text
0901c79180555528,Orphan Drug Approvals,FDA Grants Orphan Drug Status to Gevokizumab,Troy Brown,29-08-2012,"choroiditis,cyclitis,intermediate uveitis,orphan drugs,pars planitis,posterior uveitis",webmd llc index troy brown freelance writer medscape troy brown disclosed relevant financial relationship august 29 2012 u food drug administration fda granted orphan drug status gevokizumab xoma 052 xoma corp monoclonal antibody bind strongly interleukin 1 il1 treatment noninfectious intermediate uveitis posterior uveitis panuveitis chronic noninfectious anterior uveitis orphan drug act 1983 passed encourage company develop treatment rare disease disease affect fewer 200000 people united state market small treatment unprofitable develop company develop orphan drug receive 50 tax credit cost conducting human clinical trial 7year marketing exclusivity incentive behets disease rare multisystem disease cause blood vessel inflammation throughout body common symptom mouth sore genital sore type panuveitis known behets uveitis inflammation uvea retina vitreous humor lead retinal detachment vitreous hemorrhage glaucoma blindness genetic association shown behets disease il1 gene cluster il1 implicated mediator behets disease pathogenesis christine kay md director retinal clinical research director electrophysiology service vitreoretinal division department ophthalmology university florida gainesville told medscape medical news dr kay clinical correspondent american academy ophthalmology gevokizumab regulates activation il1 receptor intravenously subcutaneously administered dr kay added patient behets uveitis treatment option currently 2 drug fdaapproved treatment chronic noninfectious intermediate posterior panuveitis retisert bausch lomb ozurdex allergan extendedrelease corticosteroid ocular implant dr kay said result proofofconcept phase 2 trial intravenous gevokizumab 7 patient behets uveitis published april issue annals rheumatic disease trial patient given single infusion gevokizumab 03 mgkg patient experienced complete reduction intraocular inflammation 4 21 day median 14 day treatmentrelated adverse event clinical trial far gevokizumab studied nearly 500 patient study shown gevokizumab welltolerated drugrelated adverse event reported fred kurland chief financial officer xoma said email interview medscape medical news although appears gevokizumab may offer viable treatment option behets disease remains seen il1 antibody effect form noninfectious uveitis phase 3 clinical trial evaluate efficacy gevokizumab treatment noninfectious uveitis recruitment process dr kay said gevokizumab offer possibility pathophysiologydriven targeted therapy il1 related uveitis proven safe effective phase 3 trial could provide valuable option treatment noninfectious intermediate uveitis posterior uveitis panuveitis even drug shown effective behets disease could provide useful targeted treatment extremely aggressive condition perhaps limiting broader toxic immunosuppression dr kay said potential indication il1 inhibitor gevokizumab potential large number indication driven inflammation noninfectious uveitis also engaged 2 proofofconcept phase 2 trial using gevokizumab patient moderate severe acne vulgaris erosive osteoarthritis hand initiate third proofofconcept trial another indication later year kurland explained respect noninfectious uveitis market specifically estimate approximately 150000 patient united state noninfectious uveitis kurland added noting discussing drug pricing yet dr kay disclosed relevant financial relationship
